Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Non Hodgkin Lymphoma (NHL) Market Through 2029?

In recent times, the market size for non-Hodgkin lymphoma (NHL) has seen significant growth. By 2025, it is projected to increase from $10.11 billion in 2024 to $10.86 billion with a compound annual growth rate (CAGR) of 7.5%. The historic surge in growth is linked to a higher occurrence of NHL, advancements in diagnostic tools, immunotherapy and chemotherapy, along with enhanced clinical research, drug development, and improved survival rates.

The market for non hodgkin lymphoma (NHL) is predicted to undergo significant expansion in the forthcoming years. By 2029, it is estimated to reach a valuation of $15 billion, growing at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth during the forecast period is due to factors such as an increasing elderly population, progress in targeted treatments, breakthroughs in immunotherapy, the development of precision medicine, and heightened awareness leading to early diagnosis. The forecast period also expects to see trends such as the emergence of biosimilars, the integration of next-generation sequencing, the increased use of car-t cell therapies, the development of new chemotherapy drugs, and an emphasis on real-world evidence and outcome studies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Market Forces Are Driving The Non Hodgkin Lymphoma (NHL) Sector In 2025 And Beyond?

The non-Hodgkin lymphoma market is predicted to experience growth due to the high rate of the disease’s occurrence. Non-Hodgkin lymphoma is a form of cancer that arises from the lymphatic system – a part of the body’s immune framework. The disease’s prevalence signifies the count of people in a population presently living with or diagnosed with the condition at a particular time. Treatments for non-Hodgkin lymphoma enhance the health outcomes of those diagnosed, focusing on controlling and managing the cancerous cells. To illustrate, the American Cancer Society, a cancer healthcare organization from the US, reported in January 2023 that non-Hodgkin lymphoma makes up 4% of all cancers and approximated that in 2023, about 80,550 Americans, including 44,880 males and 35,670 females, would be impacted by the disease. It also projected the death of about 20,180 people in the same year due to non-Hodgkin lymphoma. Furthermore, the Canadian Cancer Society, a national cancer charity in Canada, reported in May 2022 that 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in the year 2022, and 3,000 Canadians’ lives would be claimed by the disease. Hence, the non-Hodgkin lymphoma market is being invigorated by the high occurrence of the disease.

How Is The Global Non Hodgkin Lymphoma (NHL) Market Categorized By Segments?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Long-Term Trends Are Likely To Affect The Non Hodgkin Lymphoma (NHL) Market?

The emergence of novel drug innovations is a significant rising trend in the non-Hodgkin lymphoma market. Firms in the non-Hodgkin sphere are emphasizing the development of new products to maintain market dominance. For example, in December 2022, Genentech Inc., a biotechnology firm based in the US, obtained FDA authorization for Lunsumio, an innovative bispecific antibody intended for treatment of relapsed or refractory follicular lymphoma. This antibody represents a new category of cancer immunotherapy that is fixed-duration, readily accessible, and immediately available to patients, eliminating any waiting time for treatment. The FDA’s endorsement is founded on optimistic outcomes from the Lunsumio Phase II GO29781 study conducted on individuals extensively pretreated for FL, especially those at a heightened risk of disease progression or unresponsive to prior therapies.

Which Firms Are Considered Leaders In The Non Hodgkin Lymphoma (NHL) Market Space?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

What Role Do Regional Policies And Investments Play In Non Hodgkin Lymphoma (NHL) Market Expansion?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model